[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RS57390B1 - Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja - Google Patents

Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja

Info

Publication number
RS57390B1
RS57390B1 RS20180807A RSP20180807A RS57390B1 RS 57390 B1 RS57390 B1 RS 57390B1 RS 20180807 A RS20180807 A RS 20180807A RS P20180807 A RSP20180807 A RS P20180807A RS 57390 B1 RS57390 B1 RS 57390B1
Authority
RS
Serbia
Prior art keywords
neuroactive
alkoxy
useful
treatment
methods
Prior art date
Application number
RS20180807A
Other languages
English (en)
Inventor
Douglas Covey
Albert Jean Robichaud
Original Assignee
Univ Washington
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Sage Therapeutics Inc filed Critical Univ Washington
Publication of RS57390B1 publication Critical patent/RS57390B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0029—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
RS20180807A 2012-12-18 2013-12-18 Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja RS57390B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261738822P 2012-12-18 2012-12-18
EP13865411.6A EP2935307B1 (en) 2012-12-18 2013-12-18 Neuroactive 19-alkoxy-17-substituted steroids, useful in methods of treatment
PCT/US2013/076214 WO2014100228A1 (en) 2012-12-18 2013-12-18 Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same

Publications (1)

Publication Number Publication Date
RS57390B1 true RS57390B1 (sr) 2018-09-28

Family

ID=50979162

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180807A RS57390B1 (sr) 2012-12-18 2013-12-18 Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja

Country Status (27)

Country Link
US (7) US9630986B2 (sr)
EP (3) EP3392260B1 (sr)
JP (4) JP6542127B2 (sr)
KR (3) KR101993899B1 (sr)
CN (3) CN105026415B (sr)
AU (5) AU2013361485B2 (sr)
BR (1) BR112015014397B1 (sr)
CA (1) CA2895513C (sr)
CY (1) CY1121150T1 (sr)
DK (1) DK2935307T3 (sr)
ES (2) ES2680582T3 (sr)
HK (1) HK1216255A1 (sr)
HR (1) HRP20181048T1 (sr)
HU (1) HUE039057T2 (sr)
IL (3) IL278396B2 (sr)
LT (1) LT2935307T (sr)
MX (2) MX365644B (sr)
NZ (2) NZ709211A (sr)
PH (2) PH12018502141A1 (sr)
PL (1) PL2935307T3 (sr)
PT (2) PT3392260T (sr)
RS (1) RS57390B1 (sr)
RU (1) RU2663665C2 (sr)
SG (3) SG10201809638YA (sr)
SI (2) SI2935307T1 (sr)
TR (1) TR201808616T4 (sr)
WO (1) WO2014100228A1 (sr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120107533A (ko) 2005-11-28 2012-10-02 마리누스 파마슈티컬스 ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도
FI2753632T3 (fi) 2011-09-08 2023-08-02 Sage Therapeutics Inc Neuroaktiivisia steroideja, koostumuksia ja niiden käyttöjä
ES2738526T3 (es) 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
IL298436B2 (en) 2012-01-23 2024-07-01 Sage Therapeutics Inc Pharmaceutical preparations that include allopregnanolone
IL294306B2 (en) 2012-08-21 2024-01-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
IL278396B2 (en) 2012-12-18 2024-07-01 Washington University St Louis Neuroactive steroids converted at the 19th position to the 17th position, their prodrugs, and methods of treatment using them
PT3461834T (pt) 2013-03-13 2021-09-10 Sage Therapeutics Inc Esteroides neuroativos
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
ES2886182T3 (es) 2013-04-17 2021-12-16 Sage Therapeutics Inc C21-N-pirazolil-esteroide 19-nor C3,3-disustituido para su uso en terapia
HUE051403T2 (hu) 2013-04-17 2021-03-01 Sage Therapeutics Inc Neuroaktív 19-nor-szteroidok kezelési eljárásokhoz
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
AU2014290400B2 (en) * 2013-07-19 2019-12-05 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
BR112016003862B1 (pt) 2013-08-23 2022-09-06 Sage Therapeutics, Inc Compostos esteroides neuroativos, suas composições e seus usos
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016061527A1 (en) 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
ME03809B (me) 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
RS60343B1 (sr) 2014-11-27 2020-07-31 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
ES2857082T3 (es) 2015-01-26 2021-09-28 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos del SNC
EP4155314A1 (en) * 2015-02-20 2023-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
SG10202002655VA (en) 2015-07-06 2020-05-28 Sage Therapeutics Inc Oxysterols and methods of use thereof
IL256710B2 (en) 2015-07-06 2024-01-01 Sage Therapeutics Inc Oxysterols and methods of using them
MA42409A (fr) 2015-07-06 2018-05-16 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
CN108135838A (zh) 2015-10-16 2018-06-08 马瑞纳斯制药公司 包含纳米粒的可注射神经类固醇制剂
WO2017087864A1 (en) * 2015-11-20 2017-05-26 Sage Therapeutics, Inc. Compounds and methods of their use
BR112018067998A2 (pt) 2016-03-08 2019-04-16 Sage Therapeutics, Inc. esteróides neuroativos, composições e usos destes
SI3436022T1 (sl) 2016-04-01 2022-08-31 Sage Therapeutics, Inc. Oksisteroli in postopki za uporabo le-teh
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3481846T3 (pl) 2016-07-07 2021-12-20 Sage Therapeutics, Inc. 11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA
AU2017296295B2 (en) 2016-07-11 2022-02-24 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
ES2965214T3 (es) 2016-07-11 2024-04-11 Sage Therapeutics Inc Esteroides neuroactivos sustituidos en C17, C20 y C21 y sus procedimientos de utilización
US20180042903A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
CN115974954A (zh) 2016-08-23 2023-04-18 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
EP3519422B1 (en) 2016-09-30 2022-08-31 Sage Therapeutics, Inc. C7 substituted oxysterols and these compounds for use as nmda modulators
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
CN110072874B (zh) 2016-10-18 2022-08-12 萨奇治疗股份有限公司 氧甾醇及其使用方法
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CN109988210B (zh) * 2017-12-30 2022-05-17 天津药业研究院股份有限公司 一种黄体酮和黄体酮中间体的制备方法
AU2019357040A1 (en) 2018-10-12 2021-05-20 Sage Therapeutics, Inc. Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders
CN109289095B (zh) * 2018-11-23 2021-03-26 淮海工学院 一种含盐酸利多卡因的肠镜凝胶剂及其制备方法
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CA3139554A1 (en) 2019-05-31 2020-12-03 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
CN114728012A (zh) 2019-08-05 2022-07-08 马瑞纳斯制药公司 用于治疗癫痫持续状态的加奈索酮
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
CN114828889A (zh) 2019-12-06 2022-07-29 马瑞纳斯制药公司 用于治疗结节性硬化症的加奈索酮
IL296645A (en) 2020-03-25 2022-11-01 Sage Therapeutics Inc Use of substances to treat respiratory conditions
CN117801047A (zh) * 2023-01-19 2024-04-02 北京华睿鼎信科技有限公司 神经甾体衍生物及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB820780A (en) * 1954-12-08 1959-09-23 Syntex Sa Cyclopentanophenanthrene derivatives
US2856415A (en) * 1957-11-13 1958-10-14 Searle & Co 3,19-dihydroxy-5-androstene derivatives
NL292848A (sr) * 1962-05-16
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
US4239681A (en) * 1974-04-15 1980-12-16 Richardson-Merrell Inc. Androst-4-en-19-ols
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
US4139617A (en) * 1974-05-13 1979-02-13 Richardson-Merrell Inc. 19-Oxygenated-androst-5-enes for the enhancement of libido
US4022769A (en) * 1974-05-13 1977-05-10 Richardson-Merrell Inc. Androst-4-en-19-ones
DE2632677A1 (de) 1976-07-16 1978-01-26 Schering Ag Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung
MA18433A1 (fr) * 1978-05-26 1979-12-31 Ciba Geigy Ag Procede pour la synthese de la chaine laterale hydroxyacetyle de steroides du type pregnagne, nouveaux 21-hydroxy-20-oxo-17 alpha-pregnagnes et produits pharmaceutiques en renfermant
US4389345A (en) 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US4495102A (en) * 1982-09-03 1985-01-22 G. D. Searle & Co. Aminoalkyl steroids
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
EP0656365B1 (en) 1993-12-02 1997-04-09 Akzo Nobel N.V. Substituted 2beta-morpholinoandrostane derivatives
US5661141A (en) * 1995-03-27 1997-08-26 Petrow; Vladimir 19-oxygenated steroids as therapeutic agents
NZ310850A (en) 1995-06-06 1999-07-29 Cocensys Inc 3 alpha hydroxy(17)-unsubstituted derivatives of androstane and 21 substituted derivatives of the pregnane series and medicaments
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US6855836B2 (en) 2000-10-26 2005-02-15 Jenapharm Gmbh & Co. Kg 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds
DE60128251T2 (de) 2000-11-03 2008-01-10 Washington University Östronderivate mit zellschützender wirkung
GR1003861B (el) * 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
DK1608671T3 (da) 2003-03-24 2010-05-10 Sterix Ltd Østrogenderivater som inhibitorer af steroidsulfatase
CN1281561C (zh) * 2003-04-23 2006-10-25 中国科学院上海有机化学研究所 一种具有1，6－亚甲基－[10]－轮烯基本骨架的化合物及其用途
WO2005000869A1 (en) * 2003-05-29 2005-01-06 Washington University Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids
US20070099880A1 (en) 2003-11-24 2007-05-03 Blizzard Timothy A Estrogen receptor modulators
CN100376685C (zh) * 2005-01-14 2008-03-26 天津科技大学 微生物转化法制备雌酚酮的方法
WO2006110642A2 (en) * 2005-04-07 2006-10-19 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
DE102007027636A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
ES2589139T3 (es) 2007-06-15 2016-11-10 Research Triangle Institute Esteroides de androstano y pregnano con potentes propiedades de modulación alostérica del complejo receptor GABA/ionóforo cloruro
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
WO2012013816A1 (en) * 2010-07-30 2012-02-02 Medexis S.A. Compounds and methods for treating neoplasia
EP2667876A2 (en) 2010-12-15 2013-12-04 Harbor BioSciences, Inc. Methods and compounds for preparing 3alpha-oxygen substituted steroids
US9388210B2 (en) 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
US9851309B2 (en) 2011-03-23 2017-12-26 Satoshi Watabe Ultra-high-sensitive assay of protein and nucleic acid and kit, and novel enzyme substrate
US20150175651A1 (en) * 2012-06-15 2015-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2014058736A1 (en) * 2012-10-08 2014-04-17 Washington University Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
IL278396B2 (en) * 2012-12-18 2024-07-01 Washington University St Louis Neuroactive steroids converted at the 19th position to the 17th position, their prodrugs, and methods of treatment using them
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
BR112016003862B1 (pt) * 2013-08-23 2022-09-06 Sage Therapeutics, Inc Compostos esteroides neuroativos, suas composições e seus usos

Also Published As

Publication number Publication date
EP2935307A1 (en) 2015-10-28
IL239501A0 (en) 2015-08-31
IL278396A (en) 2020-12-31
US20170152282A9 (en) 2017-06-01
WO2014100228A1 (en) 2014-06-26
CN109970833B (zh) 2022-05-27
AU2024202233A1 (en) 2024-05-02
US20170190732A1 (en) 2017-07-06
KR20190076072A (ko) 2019-07-01
PT2935307T (pt) 2018-07-31
IL278396B1 (en) 2024-03-01
RU2015129546A (ru) 2017-01-24
DK2935307T3 (en) 2018-07-30
JP2016503793A (ja) 2016-02-08
KR20150100771A (ko) 2015-09-02
EP2935307A4 (en) 2016-08-03
AU2018217213B2 (en) 2020-03-12
HRP20181048T1 (hr) 2018-08-24
AU2013361485B2 (en) 2018-05-17
ES2933987T3 (es) 2023-02-15
HK1216255A1 (zh) 2016-10-28
TR201808616T4 (tr) 2018-07-23
NZ739760A (en) 2020-05-29
CN105026415A (zh) 2015-11-04
LT2935307T (lt) 2018-07-25
JP2023071910A (ja) 2023-05-23
US9630986B2 (en) 2017-04-25
MX365644B (es) 2019-06-10
US20210308149A1 (en) 2021-10-07
CN109970833A (zh) 2019-07-05
AU2013361485A1 (en) 2015-07-09
HUE039057T2 (hu) 2018-12-28
EP2935307B1 (en) 2018-04-25
US20150315230A1 (en) 2015-11-05
KR101993899B1 (ko) 2019-09-24
SG10201706063UA (en) 2017-09-28
PH12018502141A1 (en) 2019-04-15
BR112015014397B1 (pt) 2021-02-02
EP3392260A1 (en) 2018-10-24
IL278396B2 (en) 2024-07-01
JP7241792B2 (ja) 2023-03-17
SG10201809638YA (en) 2018-11-29
CN114605486A (zh) 2022-06-10
MX2015007900A (es) 2016-02-05
KR102400891B1 (ko) 2022-05-20
SG11201504848QA (en) 2015-07-30
CY1121150T1 (el) 2020-05-29
PT3392260T (pt) 2022-12-27
NZ709211A (en) 2018-02-23
AU2018217213A1 (en) 2018-08-30
EP3392260B1 (en) 2022-09-21
AU2020202016A1 (en) 2020-04-09
JP2019182870A (ja) 2019-10-24
ES2680582T3 (es) 2018-09-10
PH12015501404A1 (en) 2015-09-07
MX2019006739A (es) 2019-08-22
KR102265408B1 (ko) 2021-06-16
CA2895513A1 (en) 2014-06-26
US10342809B2 (en) 2019-07-09
IL310501A (en) 2024-03-01
JP6852118B2 (ja) 2021-03-31
KR20210072151A (ko) 2021-06-16
US9676812B2 (en) 2017-06-13
CN105026415B (zh) 2019-02-01
JP2021098739A (ja) 2021-07-01
CA2895513C (en) 2021-04-27
AU2020202016C1 (en) 2022-03-24
SI2935307T1 (en) 2018-08-31
US20230190770A1 (en) 2023-06-22
EP4086270A1 (en) 2022-11-09
SI3392260T1 (sl) 2023-01-31
AU2021290223A1 (en) 2022-01-20
US20140235600A1 (en) 2014-08-21
AU2020202016B2 (en) 2021-09-23
IL239501B (en) 2020-11-30
PL2935307T3 (pl) 2018-09-28
JP6542127B2 (ja) 2019-07-10
PH12015501404B1 (en) 2015-09-07
RU2663665C2 (ru) 2018-08-08
AU2021290223B2 (en) 2024-01-18
US20200113916A1 (en) 2020-04-16
US20170232006A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
IL278396A (en) Neuroactive steroids converted at the 19th position to the 17th position, their prodrugs, and methods of treatment using them
EP2861538A4 (en) BIO CONVERSION PROCESSES AND DEVICES
PL2892525T3 (pl) Sposoby leczenia dystrofii mięśniowej
GB201110783D0 (en) Methods and uses
GB201221329D0 (en) Dermatitis treatment
HK1207007A1 (en) Method of treatment of wrinkles using topical chemodenervating agents
GB2497886B (en) Hair treatment methods
HK1199458A1 (en) Sterol derivative, preparation method therefor and use thereof
EP2837624A4 (en) 4-SUBSTITUTE-2-HYDROXYLMORPHOLIN-3-ON AND METHOD OF MANUFACTURING THEREOF
GB201213782D0 (en) Process and dressing
GB201213778D0 (en) Process and dressng
HK1204977A1 (en) Treatment for high cholesterol
HK1201726A1 (en) Treatment method for steroid responsive dermatoses
GB2500999B (en) Hair treatment methods
SG11201402309YA (en) Process for medical components and uses thereof
GB201108490D0 (en) Methods and uses
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201205449D0 (en) Treatment process
GB201206330D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201212604D0 (en) New treatment